ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Adlai Nortye Announces First Patient Dosed in Phase Ia Clinical Trial of AN2025 and AN0025 in Combination with atezolizumab for Advanced Solid Tumors
September 13, 2021NORTH BRUNSWICK, New Jersey and HANGZHOU, China, Sept. 8, 2021 /PRNewswire/ -- Adlai Nortye, a global biopharmaceutical company focused on developing innovative oncology drugs... -
Adlai Nortye Announces First Patient Dosed in Global Phase III Clinical Trial of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic Head and Neck Squamous
April 15, 2021Adlai Nortye, a global biopharmaceutical company focused on developing innovative oncology drugs, today announced that the first patient has been dosed in the global phase III clinical trial (BURAN) at Shanghai Eastern Hospital Medical Center in China.
Pharma Sources Insight January 2025
